---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008707"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:20:36.888509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA completes Phase 1 dosing of Ketamir-2; no serious AEs; plans Phase 2a in CIPN

## Summary
- Completed Phase 1 study in 56 healthy volunteers; no serious adverse events or dose-limiting toxicities.
- No clinically significant dissociative or psychotomimetic effects typically seen with ketamine observed.
- Plans to submit Phase 2a proof-of-concept study to FDA in H1 2026 for chemotherapy-induced peripheral neuropathy (CIPN).
- CIPN lacks FDA-approved therapies; Ketamir-2 is a selective oral NMDA receptor modulator.

## SEC filing metadata
- accession: 0001493152-26-008707
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226008707/0001493152-26-008707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226008707/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008707
- JSON: https://secwatch.observer/filing/0001493152-26-008707.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.